NCT00427583终止2 期
An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated.
研究概览
简要总结
This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
STI571
Experimental
干预措施: imatinib mesylate (Drug)
结局指标
主要结局
Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated.
时间窗: Every 36 weeks
次要结局
- Time to progression assessed by an MRI scan.(Every 36 weeks)
- Overall survival(Every 36 weeks)
- Safety and tolerability assessed by abnormal lab values (hematology, biochemistry, urinalysis), by physical examination and vital signs(Every 36 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)AMLNCT00707408Nantes University Hospital15
已完成
2 期
Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic LeukemiaLeukemia, Lymphoblastic, AcuteNCT02888990Versailles Hospital71
已完成
2 期
Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in ChildrenPhiladelphia ChromosomeAcute Lymphoblastic LeukemiaNCT00287105Rennes University Hospital49
已完成
1 期
Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell TumorsRefractory Desmoplastic Small Round Cell TumorsNCT00417807Novartis Pharmaceuticals9
已完成
2 期
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaPhiladelphia Chromosome Positive Acute Lymphocytic LeukemiaNCT00154349Novartis Pharmaceuticals8